Wir sind mit live! Mehr erfahren

Veracyte

VCYT

Börsenwert 3,47 Mrd. $

43,12 USD

-1,27

2,86 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

43,11

-0,01

0,02 %

1 Tag

-2,86 %

5 Tage

-4,56 %

1 Monat

12 %

3 Monate

-27,19 %

6 Monate

30,55 %

Seit Jahresbeginn

1,72 %

1 Jahr

20,41 %

5 Jahre

-4,5 %

10 Jahre

468,12 %

Profil: Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).

Mitarbeiter: 755

Gesundheitswesen Diagnostik & Research

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 26,3 %

Neutral 52,6 %

Negativ 21,1 %

Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test

Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer Milestone supports broader U.S. adoption of Prosigna and expands access for eligible patients with early-stage breast cancer

Veracyte Secures Medicare Reimbursement for Prosigna Breast Risk of Recurrence Test

Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter 2026 after the close of market on Wednesday, November 4, 2026.

Veracyte to Release Third Quarter 2026 Financial Results on November 4, 2026

Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting.

Phase III Trial Demonstrates Veracyte's Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensification Six oral presentations and two posters will highlight Decipher's prognostic and predictive value in identifying patients' risk of progression and likelihood of benefiting from treatment intensification

Veracyte Announces Eight Decipher-Focused Studies to Be Presented at ASTRO 2026

Zacks Investment Research

Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?

Veracyte (VCYT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Veracyte (VCYT) Surges 10.8%: Is This an Indication of Further Gains?

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Veracyte, Inc. (VCYT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey Acquisition positions Veracyte to deliver powerful genomic insights from urine, tissue, and blood to help guide bladder cancer care across the patient journey

Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

Zacks Investment Research

3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes

GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likely to challenge adoption across healthcare.

3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.

Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Zacks Investment Research

Is it Worth Adding Veracyte Stock to Your Portfolio Now?

VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.

Is it Worth Adding Veracyte Stock to Your Portfolio Now?

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt